Cancer Network Staff

The CHMP’s recommendation for approving teclistamab plus daratumumab in this multiple myeloma population is based on data from the phase 3 MajesTEC-3 study.

Guilherme Fleury Perini, MD, PhD, discussed KEYFORM-008 findings on favezelimab/pembrolizumab vs chemotherapy in PD-1–refractory classic Hodgkin lymphoma.

INELDA-certified death doula Kim Stravers shares a detailed account of supporting a patient with pancreatic cancer and Lynch syndrome.

Preliminary data from the phase 1/2 TARGET-D 101 trial showed a manageable safety profile for VS-7375 across KRAS G12D–mutated solid tumors.

Retrospective data showed that GLP-1 receptor agonist use was associated with a 51% reduction in colorectal cancer odds among patients with inflammatory bowel disease.

Zanzalintinib plus atezolizumab did not elicit a statistically significant overall survival advantage over regorafenib in patients with non–MSI-H mCRC without active liver metastases.

Kim Stravers, an INELDA-certified death doula and educator, explains how end-of-life doulas provide nonmedical emotional, practical, and relational support to patients with cancer and their families.

“I love that our field is taking an ambitious swing at how best to take care of patients who are older and less fit with large cell lymphoma,” said Matthew Matasar, MD, chief in the division of Blood Disorders, Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center, and professor of medicine at Rutgers Robert Wood Johnson Medical School.

Binimetinib tablets at 45 mg received tentative FDA approval for patients with melanoma and NSCLC.

The European Commission has approved encorafenib plus cetuximab and FOLFOX as the first BRAF-targeted regimen authorized in the EU for first-line BRAF V600E–mutant metastatic colorectal cancer.

TRIDENT failed to show an OS benefit for TTFields started during chemoradiation vs the maintenance-phase approach in newly diagnosed glioblastoma.

New ASCO 2026 data reinforced the importance of multidisciplinary coordination and patient-centered decision-making when considering cystectomy omission.

Updated NCCN guidelines for CNS cancers now recommend CSF-based tumor-derived DNA testing for patients with biopsy-infeasible high-grade glioma or glioblastoma.

A phase 3 trial with givastomig plus nivolumab and chemotherapy in first-line HER2-negative metastatic gastric cancer is planned in Q4 2026.

Treatment with ADCs for metastatic TNBC comes with a unique set of toxicities, and know how to manage, or adjust treatment as needed is important.

Panelists discussed 4 trials, which focused on 3 different ADCs and how each one is being utilized in their clinical practice.

The phase 2 AMPLIFY-7P trial did not meet its primary DFS end point, though post-hoc analyses identified a benefit in R0-resected patients with mKRAS PDAC.

The FDA has accepted the BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.

Emmanuel Bachy, MD, PhD, shared data from a phase 1b study evaluating subcutaneous mosunetuzumab plus lenalidomide in untreated follicular lymphoma.

The FDA has approved gadoquatrane for contrast-enhanced MRI to detect lesions with abnormal vascularity in the central nervous system and body.

Early interim data from the 3 patients with recurrent glioblastoma showed 100% local disease control and a 67% complete response rate with Alpha DaRT.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

In BRUIN CLL-322, fixed-duration pirtobrutinib plus venetoclax/rituximab improved PFS vs venetoclax/rituximab in relapsed/refractory CLL.

In KOMET-007, ziftomenib plus 7+3 produced high responses and MRD-negativity rates in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.

The phase 3 EPCORE DLBCL-1 data showed epcoritamab reduced progression or death risk by 26% vs chemoimmunotherapy in relapsed/refractory LBCL.

In MonumenTAL-3, talquetamab plus daratumumab with or without pomalidomide significantly improved PFS vs DPd in relapsed/refractory myeloma.

Atezolizumab plus chemotherapy reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone in this patient population.

A phase 1b/2 trial of azacitidine, venetoclax, and ivosidenib showed composite complete remissions and MRD negativity in newly diagnosed IDH1-mutated AML.

Phase 3 results support anbenitamab plus albumin-bound docetaxel as a new treatment option in HER2-positive breast cancer across disease stages.

Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.